{"success":true,"data":{"pressRelease":{"id":"17020","rtpr_id":"nPn7xPf5a","ticker":"LUCD","exchange":"NASDAQ","all_tickers":["LUCD","PAVM"],"title":"PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026","author":"PR Newswire","published_at":"2026-05-01T12:31:00.028Z","article_body":"PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026\n\nPR Newswire\n\nNEW YORK, May 1, 2026\n\nConference Call and Webcast at 8:30 AM ET\n\nNEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=1074387465&u=https%3A%2F%2Fpavmed.com%2F&a=PAVmed+Inc.)\n (Nasdaq: PAVM) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage\nmedical technology company, operating in the medical device, diagnostics, and\ndigital health sectors, today announced that it will host a business update\nconference call and webcast on Friday, May 15, 2026, at 8:30 AM ET. During the\ncall, Lishan Aklog, M.D.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=2564316818&u=https%3A%2F%2Fwww.pavmed.com%2Four-company%2Fleadership&a=Lishan+Aklog%2C+M.D.)\n, PAVmed's Chairman and Chief Executive Officer, will provide a business\nupdate and discuss the Company's operations and growth strategy. In\naddition, Dennis McGrath\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=2080124376&u=https%3A%2F%2Fwww.pavmed.com%2Four-company%2Fleadership&a=Dennis+McGrath)\n, PAVmed's President and Chief Financial Officer, will discuss the Company's\nfirst quarter 2026 financial results.\n\n(https://mma.prnewswire.com/media/2011714/PAVmed_updated_Logo.html)\n\nThe webcast will be available at the investor relations section of the\nCompany's website at pavmed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=271994006&u=http%3A%2F%2Fir.pavmed.com%2F&a=pavmed.com)\n.  Alternatively, to access the conference call by telephone, U.S.-based\ncallers should dial 1-800-836-8184 and international listeners should dial\n1-646-357-8785. All listeners should provide the operator with the conference\ncall name \"PAVmed Business Update\" to join.\n\nFollowing the conclusion of the conference call, a replay will be available\nfor 30 days on the investor relations section of the Company's website at\npavmed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=271994006&u=http%3A%2F%2Fir.pavmed.com%2F&a=pavmed.com)\n.\n\nAbout PAVmed\nPAVmed Inc. is a diversified commercial-stage medical technology company\noperating in the medical device, diagnostics, and digital health sectors. Its\nsubsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer\nprevention medical diagnostics company that markets the\nEsoGuard(®) Esophageal DNA Test and EsoCheck(®) Esophageal Cell Collection\nDevice—the first and only commercial tools for widespread early detection of\nesophageal precancer to mitigate the risks of esophageal cancer deaths. Its\nother subsidiary, Veris Health Inc., is a digital health company focused on\nenhanced personalized cancer care through remote patient monitoring using\nimplantable biologic sensors with wireless communication along with a custom\nsuite of connected external devices. Veris is concurrently developing an\nimplantable physiological monitor, designed to be implanted alongside a\nchemotherapy port, which will interface with the Veris Cancer Care Platform.\n\nFor more information about PAVmed, please visit pavmed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=74165319&u=http%3A%2F%2Fwww.pavmed.com%2F&a=pavmed.com)\n.\n\nFor more information about Lucid Diagnostics, please visit luciddx.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=1865928605&u=http%3A%2F%2Fwww.luciddx.com%2F&a=luciddx.com)\n.\n\nFor more information about Veris Health, please visit verishealth.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=1845880745&u=http%3A%2F%2Fwww.verishealth.com%2F&a=verishealth.com)\n.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/pavmed-to-hold-first-quarter-2026-business-update-conference-call-and-webcast-on-may-15-2026-302760042.html\n(https://www.prnewswire.com/news-releases/pavmed-to-hold-first-quarter-2026-business-update-conference-call-and-webcast-on-may-15-2026-302760042.html)\n\nSOURCE PAVmed Inc.\n\n\n\nInvestor and Media Contact: Matt Riley, Vice President, Investor Relations, PAVmed, Lucid Diagnostics, and Veris Health, mjr@pavmed.com\n\nPhoto: \nhttps://mma.prnewswire.com/media/2011714/PAVmed_updated_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn7xPf5a","title":"PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026","author":"PR Newswire","ticker":"LUCD","created":"2026-05-01T12:31:00.028Z","tickers":["LUCD","PAVM"],"exchange":"NASDAQ","article_body":"PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026\n\nPR Newswire\n\nNEW YORK, May 1, 2026\n\nConference Call and Webcast at 8:30 AM ET\n\nNEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=1074387465&u=https%3A%2F%2Fpavmed.com%2F&a=PAVmed+Inc.)\n (Nasdaq: PAVM) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage\nmedical technology company, operating in the medical device, diagnostics, and\ndigital health sectors, today announced that it will host a business update\nconference call and webcast on Friday, May 15, 2026, at 8:30 AM ET. During the\ncall, Lishan Aklog, M.D.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=2564316818&u=https%3A%2F%2Fwww.pavmed.com%2Four-company%2Fleadership&a=Lishan+Aklog%2C+M.D.)\n, PAVmed's Chairman and Chief Executive Officer, will provide a business\nupdate and discuss the Company's operations and growth strategy. In\naddition, Dennis McGrath\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=2080124376&u=https%3A%2F%2Fwww.pavmed.com%2Four-company%2Fleadership&a=Dennis+McGrath)\n, PAVmed's President and Chief Financial Officer, will discuss the Company's\nfirst quarter 2026 financial results.\n\n(https://mma.prnewswire.com/media/2011714/PAVmed_updated_Logo.html)\n\nThe webcast will be available at the investor relations section of the\nCompany's website at pavmed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=271994006&u=http%3A%2F%2Fir.pavmed.com%2F&a=pavmed.com)\n.  Alternatively, to access the conference call by telephone, U.S.-based\ncallers should dial 1-800-836-8184 and international listeners should dial\n1-646-357-8785. All listeners should provide the operator with the conference\ncall name \"PAVmed Business Update\" to join.\n\nFollowing the conclusion of the conference call, a replay will be available\nfor 30 days on the investor relations section of the Company's website at\npavmed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=271994006&u=http%3A%2F%2Fir.pavmed.com%2F&a=pavmed.com)\n.\n\nAbout PAVmed\nPAVmed Inc. is a diversified commercial-stage medical technology company\noperating in the medical device, diagnostics, and digital health sectors. Its\nsubsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer\nprevention medical diagnostics company that markets the\nEsoGuard(®) Esophageal DNA Test and EsoCheck(®) Esophageal Cell Collection\nDevice—the first and only commercial tools for widespread early detection of\nesophageal precancer to mitigate the risks of esophageal cancer deaths. Its\nother subsidiary, Veris Health Inc., is a digital health company focused on\nenhanced personalized cancer care through remote patient monitoring using\nimplantable biologic sensors with wireless communication along with a custom\nsuite of connected external devices. Veris is concurrently developing an\nimplantable physiological monitor, designed to be implanted alongside a\nchemotherapy port, which will interface with the Veris Cancer Care Platform.\n\nFor more information about PAVmed, please visit pavmed.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=74165319&u=http%3A%2F%2Fwww.pavmed.com%2F&a=pavmed.com)\n.\n\nFor more information about Lucid Diagnostics, please visit luciddx.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=1865928605&u=http%3A%2F%2Fwww.luciddx.com%2F&a=luciddx.com)\n.\n\nFor more information about Veris Health, please visit verishealth.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4676917-1&h=1845880745&u=http%3A%2F%2Fwww.verishealth.com%2F&a=verishealth.com)\n.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/pavmed-to-hold-first-quarter-2026-business-update-conference-call-and-webcast-on-may-15-2026-302760042.html\n(https://www.prnewswire.com/news-releases/pavmed-to-hold-first-quarter-2026-business-update-conference-call-and-webcast-on-may-15-2026-302760042.html)\n\nSOURCE PAVmed Inc.\n\n\n\nInvestor and Media Contact: Matt Riley, Vice President, Investor Relations, PAVmed, Lucid Diagnostics, and Veris Health, mjr@pavmed.com\n\nPhoto: \nhttps://mma.prnewswire.com/media/2011714/PAVmed_updated_Logo.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T12:31:00.070681064Z","server_sent_at_ms":1777638660070},"received_at":"2026-05-01T12:31:00.130Z","source_url":"https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-302728534.html"},"analysis":{"id":"12572","press_release_id":"17020","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"PAVmed announced it will host a business update conference call on May 15, 2026, to discuss first quarter 2026 financial results and growth strategy.\n\nCEO Dr. Lishan Aklog and CFO Dennis McGrath will lead the call, which will be accessible via webcast and telephone.\n\nA replay of the event will be available on the company's investor relations website for 30 days following the call.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine administrative announcement of upcoming earnings call."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Lishan Aklog","role":"Chairman and Chief Executive Officer"},{"name":"Dennis McGrath","role":"President and Chief Financial Officer"},{"name":"Matt Riley","role":"Vice President, Investor Relations"}],"products":["EsoGuard(®) Esophageal DNA Test","EsoCheck(®) Esophageal Cell Collection Device","Veris Cancer Care Platform","implantable physiological monitor"],"companies":[{"name":"PAVmed Inc.","ticker":"PAVM"},{"name":"Lucid Diagnostics","ticker":"LUCD","relationship":"subsidiary"},{"name":"Veris Health Inc.","relationship":"subsidiary"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of an upcoming business update and earnings conference call. No material financial results or strategic changes were disclosed in the text itself."},"tickerRelevance":{"others":[{"ticker":"PAVM","relevance":"primary"}],"primary":"LUCD"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-micro-cap","eventGravity":"administrative-announcement"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"PAVmed announced it will host a business update conference call on May 15, 2026, to discuss first quarter 2026 financial results and growth strategy.\n\nCEO Dr. Lishan Aklog and CFO Dennis McGrath will lead the call, which will be accessible via webcast and telephone.\n\nA replay of the event will be available on the company's investor relations website for 30 days following the call.","key_figures":{},"named_entities":{"people":[{"name":"Lishan Aklog","role":"Chairman and Chief Executive Officer"},{"name":"Dennis McGrath","role":"President and Chief Financial Officer"},{"name":"Matt Riley","role":"Vice President, Investor Relations"}],"products":["EsoGuard(®) Esophageal DNA Test","EsoCheck(®) Esophageal Cell Collection Device","Veris Cancer Care Platform","implantable physiological monitor"],"companies":[{"name":"PAVmed Inc.","ticker":"PAVM"},{"name":"Lucid Diagnostics","ticker":"LUCD","relationship":"subsidiary"},{"name":"Veris Health Inc.","relationship":"subsidiary"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-01T13:01:49.420Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-micro-cap","eventGravity":"administrative-announcement"}},"durationMs":24844,"modelName":"glm-4.7"}}